Scholarly Index
Felix Y. Feng
University of California, San Francisco; 48,681 total citations; 871 total publications; best world rank #5
University of California, San Francisco
48,681Total citations
871Total publications
108H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Prostate Cancer Treatment and Research | Lifetime | 65 | US 44 | 99.73 |
| Prostate Cancer Diagnosis and Treatment | Lifetime | 116 | US 69 | 99.57 |
| Cancer, Lipids, and Metabolism | Lifetime | 249 | US 136 | 98.94 |
| Radiopharmaceutical Chemistry and Applications | Lifetime | 313 | US 139 | 98.10 |
| Cancer-related molecular mechanisms research | Lifetime | 704 | US 185 | 98.04 |
| PARP inhibition in cancer therapy | Lifetime | 228 | US 115 | 96.98 |
| Advanced Radiotherapy Techniques | Lifetime | 809 | US 380 | 97.45 |
| Prostate Cancer Diagnosis and Treatment | 2021-2025 | 5 | US 3 | 99.83 |
| Prostate Cancer Treatment and Research | 2021-2025 | 8 | US 3 | 99.89 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 27 | US 10 | 99.21 |
| Radiopharmaceutical Chemistry and Applications | 2021-2025 | 83 | US 28 | 97.60 |
| Cancer Genomics and Diagnostics | 2021-2025 | 660 | US 293 | 95.94 |
| Statistical Methods in Clinical Trials | 2021-2025 | 150 | US 63 | 90.28 |
| Bladder and Urothelial Cancer Treatments | 2021-2025 | 781 | US 224 | 91.64 |
| Molecular Biology Techniques and Applications | 2021-2025 | 232 | US 50 | 85.23 |
| PARP inhibition in cancer therapy | 2021-2025 | 590 | US 225 | 84.80 |